Business Wire

Bayer to Unveil New Data From Its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated With Menopause

Christian Seitz Thursday, September 12, 06:15 PM to 7:15 PM CT, Location: Riverside East, Riverside West/South – Exhibit Hall Level- East Tower Poster #122: “Do sleep disturbances have an impact on ...
Nasdaq

Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot flashes due to menopause1 In OASIS 1 and OASIS 2, ...
GEN

Bayer, Kumquat Target KRAS Variant in Up-to-$1.3B+ Cancer Collaboration

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor through a collaboration that could generate up to $1.3 billion-plus for the San Diego biotech, while bolstering ...
Hosted on MSN

Bayer to Pay $1.3 Billion for Cancer Medicine in Pharma Push

(Bloomberg) -- Bayer AG agreed to pay Kumquat Biosciences Inc. as much as $1.3 billion to gain a potential new cancer medicine and boost its pharma division’s growth prospects. The German company will ...
Barron's

Bayer In $1.3 Bn Deal For Cancer Drug Candidate

German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech company to develop its prospective cancer drug. The ...